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Mechanisms underlying radiation and chemotherapy
resistance, the hallmark of human melanoma, are not
well understood. Here we demonstrate that expression
levels of signal adaptor protein TRAF2 coincide with
melanoma resistance to UV-irradiation. Altered TRAF2
signaling by a form of TRAF2, which lacks the ring
finger domain (TRAF2DN), increases activities of p38
MAPK, ATF2, and the level of TNFa expression.
Forced expression of TRAF2DN in HHMSX highly
metastatic melanoma cells that lack Fas expression and
thus utilize the TNFa-TNFR1 as the major apoptotic
pathway sensitized cells to UV-induced apoptosis. An
over twofold increase in degree of apoptosis was
observed in TRAF2DN expressing cells that were
treated with actinomycin D, anisomycin or with the
radiomimetic drug neocarzinostatin. Sensitization by
TRAF2DN is selective since it was not observed in
response to either Taxol or cis-platinum treatment.
TRAF2DN eects are primarily mediated via p38 since
inhibition of p38 reduces, whereas activation of p38
promotes the level of UV-induced apoptosis. Conversely,
activation of IKK attenuates the sensitization of
melanoma by TRAF2DN, indicating that p38-mediated
suppression of NF-kB activity is among TRAF2DN
eects. Our finding identifies p38, TNFa and NF-kB
among key players that eciently sensitizes melanoma
cells to UV-, ribotoxic (anisomycin) and radiomimetic
chemicals-induced programmed cell death in response to
aberrant TRAF2 signaling. Oncogene (2001) 20, 2243 –
2253.
Keywords: p38; TRAF2; melanoma; apoptosis; radia-
tion; anisomycin; actinomycin D
Introduction
The incidence of malignant melanoma, a tumor, which
responds poorly to chemotherapy and irradiation, has
exponentially increased over the past decade. At
present, the nature of melanoma protection from
radiation-induced apoptosis remains largely unknown,
despite advances made in our understanding the
biology of this tumor type (Meier et al., 1998). The
ability to resist apoptosis, by re-arranging the
apoptosis machinery, including Fas, TNFR1, DR-3,
TRAIL-R1 and TRAIL-R2 (Ashkenazi and Dixit,
1998; Nagata, 1997) is characteristic of most tumor
cells, including melanomas (Peli et al., 1999). Altered
susceptibility to apoptosis was shown to include
additionally increased expression of inhibitory apopto-
sis proteins (IAP’s) that suppress caspase activity
(Deveraux and Reed, 1999). Common to late-stage
melanoma cells is the expression of a large subset of
growth factors, cytokines and their respective recep-
tors, which contribute to autocrine and paracrine
regulation of their progression (Moretti et al., 1999).
Among the latter are TNFa and TNFR1 whose
interaction elicits either death- or survival-signaling
cascades in which the signal adaptor TNFR-associated
factor2 (TRAF2) plays a primary regulatory role (Hsu
et al., 1996; Liu et al., 1996; Arch et al., 1998).
TRAF2 itself has been implicated in the activation of
distinct signaling pathways, including the NF-kB and
the p38/JNK cascades (Hsu et al., 1996; Liu et al.,
1996; Arch et al., 1998; Natoli et al., 1997; Nishitoh et
al., 1998). TNF-induced NF-kB activation can be
mediated via the adapter receptor interacting protein
(RIP), or by the NF-kB-inducing kinase (NIK) (Yuasa
et al., 1998; Galibert et al., 1998; Kelliher et al., 1998;
Lin et al., 1998; Malinin et al., 1997; Song et al., 1997).
NIK activates a multiprotein catalytic complex (IkB
kinase complex) that phosphorylates the NF-kB
inhibitor, IkBa at serines 32 and 36 (Zandi et al.,
1997). Phospho-IkBa is then targeted for proteasome-
dependent degradation via the HOS/Skip1/Cullin1/
Roc1 ubiquitin ligase complex (Maniatis, 1999; Fuchs
et al., 1999; Tan et al., 1999), thus liberating NF-kB,
which enters the nucleus and mediates NF-kB-
dependent transcription. The other TRAF2-mediated
pathway, which is independent of NIK, activates the c-
Jun amino-terminal kinases/stress activated protein
kinases (JNKs/SAPKs/p38), a family of Ser/Thr
protein kinases regulated by extracellular signals. The
Ser/Thr protein kinases stimulate transcription by
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phosphorylation and activation of a number of
transcription factors, including c-Jun, activating tran-
scription factor 2 (ATF2), p53, and ternary complex
factor (TCF)/ELK2 (Fuchs et al., 1998; Ip and Davis,
1998; Minden and Karin, 1997). Activation of SAPK
and p38 by TRAF2 is mediated by germinal center
kinase (GCK), which associates with both TRAF2 and
MEKK1 via its COOH-terminal regulatory domain
(Yuasa et al., 1998).
Fas receptor cross-linking induces apoptosis in a
caspase-dependent manner (Krammer, 2000), which
has been also implicated in the cleavage and
intracellular redistribution of MEKK1 (Deak et al.,
1998) and MAPK/JNK activation (Goillot et al.,
1997). Among possible mechanisms for JNK activation
via Fas is interaction with Daxx (Yang et al., 1997),
which disrupt the intramolecular inhibition of ASK1,
leading to the activation of MKK7/JNK. JNK has
been also implicated in the regulation of cell death
through the Fas cascade by controlling the expression
of Fas ligand (FasL), through a MEKK1-regulated
element on FasL promoter (Faris et al., 1998).
Interestingly, the activation of FasL is also NF-kB
and AP1-dependent (Kasibhatla et al., 1998), pointing
to a potential link between TRAF2 and FasL. Through
its diverse downstream targets and respective kinases,
TRAF2 has been identified as a critical component of
the cell’s ability to undergo programmed cell death in
response to TNF treatment or UV-irradiation (Tobin
et al., 1998).
In elucidating transcription factors that alter mela-
noma resistance to UV-irradiation we have identified
CREB associated proteins (Yang et al., 1996) and
ATF2 as factors that play an important role in
acquiring this resistance (Ronai et al., 1998). ATF2
confers melanoma resistance to radiation via increased
transcription and expression of TNFa which may elicit
an anti-apoptotic signal in some late-stage melanoma
cell lines. Forced expression of hypo-phosphorylated or
transcriptionally inactive forms of ATF2, which
suppress TNFa expression, is capable of sensitizing
melanoma cells to radiation-induced apoptosis (Ivanov
and Ronai, 1999). Furthermore, we have shown that
via suppression of NF-kB transcriptional activity,
ATF2 kinase – p38 down-regulates the expression of
Fas, which is the primary apoptotic receptor utilized in
most late-stage melanoma cells (Ivanov and Ronai,
2000). Thus, through coordinated increase in survival
signal and decrease in pro-apoptotic signal (Fas), p38
and its eector ATF2 confer the resistance of human
melanoma cells to radiation-induced FasL-Fas-
mediated programmed cell death. These observations
positioned p38 as a key regulator of the balance
between TNFa-TNFR and FasL-Fas death signaling
cascades, and suggest that modulating p38 activities
may assist in sensitization of melanoma cells to chemo-
and radiotherapy. Interestingly, the expression and
activities of p38 upstream regulators, TRAF2 and
GCK are altered during melanoma progression. Early-
stage melanoma cells exhibit lower levels of TRAF2
and GCK expression in response to radiation, when
compared with the more resistant and metastatic late-
stage melanomas (Ivanov et al., 2000). Given the
changes in TRAF2 expression during melanoma
development and in light of the role of TRAF2 in
the regulation of p38 catalytic activities, in the present
studies we have explored the possible use of TRAF2 as
a target to increase sensitivity of highly metastatic
melanoma cells to radiation and chemical treatment.
Results
TRAF2 expression coincides with degree of sensitivity to
UV-irradiation
Comparing five melanoma derived cell lines, which
represent dierent stages in melanoma development,
identified two (THX and WM1552) that had sub-
stantial lower levels of TRAF2 expression after UV-
irradiation (Figure 1a). Altered TRAF2 expression in
UV-treated melanoma cells does not reflect a general
pattern of protein expression. For example, the
expression of IkB, which is implicated in the regulation
of melanoma ability to undergo cell death (Ivanov and
Ronai, 2000), decreased 6 h after UV treatment, and
increased back to basal levels 18 h after treatment
(Figure 1a). Lower expression of TRAF2 after UV-
treatment coincides with the higher amount of cells
that underwent apoptosis following UV-irradiation
(Figure 1b). Forced expression of TRAF2 in THX
cells protected these cells from low-dose irradiation
(data not shown). Similarly, forced expression of
TRAF2 and GCK in the WM1552 cells eciently
increased the resistance and reduced level of apoptosis
in response to UV-irradiation (Ivanov et al., 2000).
These observations suggest that changes in TRAF2
expression coincides with altered resistance of melano-
ma cells to UV-irradiation.
Addition of antagonistic antibodies to growth
medium enables to identify which of the apoptotic
pathways, FasL-Fas- or TNFa-TNFR, mediates the
apoptotic response following exposure to UV-irradia-
tion. Whereas THX, WM1552 and HHMSX cells
exhibited 30 – 50% decrease in cell death upon attenuat-
ing the TNFR-dependent pathway (using anti-TNFR1
Abs), LU1205 was the only melanoma cell line out of
five tested here that showed noticeable (fourfold)
decrease in cell death upon addition of the anti-Fas
antagonistic antibodies (Figure 1c). Lack of a response
to antagonistic Abs against Fas in the HHMSX cells
following UV treatment (Figure 1c) coincided with
almost undetectable levels of surface Fas expression
(Figure 1d). When compared with other late-stage
melanoma cells, HHMSX cells possess relatively low
levels of the anti-apoptotic protein BclxL (Figure 1e).
Common to two (THX and WM1552) of the three
melanomas, which exhibited TNFR-mediated cell
death, is the higher sensitivity to UV-induced apoptosis
and poor expression of TRAF2 in response to UV-
irradiation. The latter coincides with inducible phos-
phorylation of p38 and increased TNFa expression
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following exposure to UV-treatment (Figure 1e and
Ivanov et al., 2000). Conversely, the more resistant
melanoma FEMX cells no longer exhibit p38 activa-
tion and TNFa expression in response to UV-treatment
(Figure 1e). This observation points to an inverse
correlation between the levels of TRAF2 expression,
p38 activities, TNFa expression, and sensitivity of
melanoma cells to radiation. This correlation was seen
in three out of the four late stage aggressive melanoma
cell lines tested, suggesting that in certain occasions,
other signaling cascades may also prevail. As an
upstream regulator of multiple stress kinases, including
p38, and subsequent eectors, including TNFa,
TRAF2 may play a central role in acquiring melanoma
resistance to UV-treatment. To test this possibility we
have selected to further characterize the highly
metastatic HHMSX cells as a representative of late-
stage melanoma cells, which constitutively express high
levels of TRAF2 and are highly resistant to UV-
irradiation and chemotherapy (data not shown).
TNFa expression is regulated by p38 and ATF2
The responsiveness to antagonistic Abs against TNFR
and TNFa in HHMSX cells led us to further explore
the regulation of TNFa expression in these cells.
Monitoring luciferase activity driven by the TNFa
promoter revealed noticeable basal activity, which
increased (threefold) in response to UV-irradiation
(Figure 2a). Point mutations within the CRE sequence
(position – 106) of the TNFa promoter (Rhoades et al.,
1992) reduced basal activities and abolished their
response to UV-irradiation. Mutation within the
AP1-binding site (position – 66) reduced degree of
luciferase activity in response to UV-treatment, albeit
to lesser extent than seen with the CRE mutant (Figure
2a). Pharmacological inhibitor of p38 catalytic activity,
SB203508, was as ecient as the CRE mutation in
abrogating the transcriptional activation mediated by
TNF-Luc construct after UV-treatment. These results
demonstrate that through the CRE site, p38 and its
Figure 1 Level of TRAF2 expression coincides with resistance to UV-irradiation. (a) Western blot analysis of TRAF2 and IkB
expression before and after UVC irradiation of indicated human melanoma cell lines. (b) Melanoma cells were UV-irradiated.
Detection of apoptosis levels was performed by PI staining and the flow cytometry 30 h later, as described in Materials and methods.
(c) Cell cultures were pretreated with mAbs against either Fas or TNFR1 2 h before UVC irradiation (80 J/m2). Data shown represent
three experiments performed in triplicates. (d) Cell surface expression of Fas was determined by anti-Fas-PE mAb and FACS analysis;
ns: nonspecific staining. (e) Western blot analysis of Phospho-p38, p38, TNFa and BclXL levels before and 3 h after UV irradiation
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substrates regulates TNFa transcription in the
HHMSX melanoma cells. Indeed, HHMSX cells
treated with the p38 inhibitor, SB203580, also exhibited
an attenuated UV-induction of ATF2-c-Jun dependent
reporter construct (5xJun2tk-Luc; Figure 2b). Inhibi-
tion of p38 catalytic activities was also reflected in
reduced ATF2 phosphorylation and a concomitant
decrease in expression of TNFa after UV-treatment
(Figure 2c). Treatment of HHMSX cells with p38
inhibitor prior to UV-irradiation has lowered degree of
UV-irradiation induced apoptosis from 17 to 10% and
from 54 to 18%, 24 and 72 h after UV-treatment,
respectively (Figure 2d), which reflects the fraction of
apoptosis that is TNF-driven in these cells. Conversely,
forced expression of a constitutive active form of p38
kinase, MKK6, led to a twofold increase in the degree
of cell death in transfected cells, whereas dominant
negative form of p38, p38-ASP, abolished UV-induced
cell death (Figure 2e). These data suggest that TNFa
expression in HHMSX cells is regulated primarily by
p38/ATF2 and that inhibition of this pathway
eciently decreases the UV-induced apoptosis.
Expression of TRAF2DN increases activities of p38 and
ATF2 and expression of TNFa after UV irradiation
Since HHMSX is among cells that exhibit stable
expression of TRAF2 following UV-treatment, and
since TRAF2 is among upstream regulators of p38 we
have elucidated the possible role of TRAF2 in
resistance of these melanoma cells to UV-induced
apoptosis. To attenuate endogenous TRAF2 activities
Figure 2 TNFa expression is regulated by p38 in HHMSX cells. (a) Role of p38 kinase and AP1- or CRE-elements and in
regulation of TNFa promoter activity. HHMSX cells (56105) were transiently co-transfected with the reporter construct 7615
TNF-Luc or its mutated CREmut, and AP1mut variants (0.5 mg) in the presence of pCMV-b-gal (0.25 mg). Twenty-four hours after
transfection cells were irradiated with UVC (60 J/m2) and after an additional 16 h, cells were analysed for luciferase and b-
galactosidase activity. Luciferase activity normalized to b-galactosidase is shown. (b) Eect of 5 mM SB203580 on UVC-induced
luciferase activity directed by 56Jun2tk-Luc construct. (c) Western blot analysis of phospho-p38, phospho-ATF2 levels and TNFa
expression in HHMSX cells following UVC irradiation in the absence or in the presence of 5 mM SB203580. (d) Apoptosis analysis
of HHMSX cells was performed 30 h after UVC (60 J/m2) irradiation as described in Materials and methods. (e) Degree of
apoptosis upon forced expression of control empty vector, p38-ASP or MKK6-DD in the presence of pGFP before and after UV-
irradiation (80 J/m2)
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we have used a truncated form of TRAF2, which lacks
the first 87 aa that contains the ring finger domain
(TRAF2DN) (Hsu et al., 1996). Expressions of
TRAF2DN results in canonical suppression of NF-kB
activity following TNFa or UVC treatment in several
melanoma cell lines, including LU1205 cells (Ivanov et
al., 2000). HHMSX cells that stably express the
truncated form of TRAF2 were established and were
characterized in comparison to control cells (neo),
transfected with the empty vector pcDNA3. Among
the HHMSX clones that stably express TRAF2DN we
have selected the cells, which exhibited higher expres-
sion levels of TRAF2DN, for further characterization
(Figure 3a). HHMSX/TRAF2DN cells exhibit notice-
able expression of TNFR1 (Figure 3a). Expression of
TRAF2DN increased and more noticeably prolonged
the duration of UV-inducible levels of p38 and ATF2
phosphorylation (Figure 3b,c). Sustained p38 kinase
activity and ATF2 transcriptional output in HHMSX/
TRAF2DN cells coincided with a threefold increase in
UV-inducible 5xJun2tk-Luc activity (which is regulated
primarily by the ATF2/c-Jun heterodimers). Similarly,
there was a twofold increase in UV-inducible TNFa
promoter activity following UVC irradiation as
monitored by the 7615 TNF-Luc construct (Figure
3d). Elevated level of 7615 TNF-Luc activity coincides
with increased expression of TNFa after UV-treatment
(Figure 3e). Conversely, UVC-dependent up-regulation
of 2xNF-kB-Luc activity was attenuated in TRAF2DN
expressing cells (Figure 3d). These observations suggest
that expression of TRAF2DN results in up-regulation
of p38/ATF2 activities and corresponding increase in
TNFa-transcription and expression.
TRAF2DN sensitizes HHMSX cells to
UV-induced apoptosis
Analysis of HHMSX response to UV-irradiation
revealed that TRAF2DN expression increased fraction
of cells that underwent apoptosis following exposure to
UVC. Increased level of UV-induced apoptosis was
attenuated upon addition of the antagonistic antibodies
to TNFa (Figure 3f). A greater portion of melanoma
cells underwent programmed cell death 64 h after UV-
irradiation (41% of the neo-transfected vs 57% of
those expressing the TRAF2DN (Figure 3f).
TRAF2DN expression also increased degree of cell
death in response to exogenous TNFa (10 ng/ml) and
cycloheximide treatment (data not shown). These
observations demonstrate that altered TRAF2 activity
increases the level of UV-mediated cells death in
melanoma cells, which utilizes TNFa-TNFR as the
primary death pathway.
Inhibition of p38 or activation of IKK attenuates
TRAFDN-mediated sensitization of melanoma cells
to UV-treatment
The finding that expression of TRAF2DN increases
p38 activities led us to determine whether the
pharmacological inhibitor of p38 will aect the
sensitization observed in the melanoma cells studied
here. Treatment of control (neo) HHMSX cells with
SB203580 prior to their exposure to UV-irradiation
attenuated the degree of UV-mediated apoptosis from
16 to 9% after 18 h and from 41 to 24% after 64 h
(Figure 4a). The pharmacological inhibitor of p38 had
greater inhibitory eect on the TRAF2DN expressing
cells (where it decreased apoptosis from 26 to 10%
after 18 h and from 57 to 30% after 64 h; Figure 4a).
These data confirm that the primary signaling cascade
that has been aected by the expression of TRAF2
lacking the ring finger domain and which contributes
to the sensitization of melanoma cells to apoptosis is
p38-dependent.
Given the ability of p38 to down-regulate the activity
of NF-kB (Ivanov and Ronai, 2000), we have next
determined the role of NF-kB in the sensitization of
melanoma cells to UV-induced apoptosis in the
presence of TRAF2DN. Forced expression of the
constitutively active form of IKKb (IKKS178E) in
HHMSX/TRAF2DN cells increased DNA binding
activity of NF-kB heterodimers p65 – p50 (Figure 4b;
LU1205 cells were used as a positive control for NF-
kB DNA-binding activity). Elevated NF-kB DNA
binding activity coincided with a noticeable increase
in NF-kB-mediated Luc activity (Figure 4c). Conse-
quently, degree of apoptosis induced by UV-irradiation
in the HHMSX/TRAF2DN cells co-expressing the IKKb
was abolished to basal levels seen prior to irradiation
(Figure 4d). These data suggest that the sensitization of
HHMSX melanoma cells to UVC irradiation by
TRAF2DN is mediated via suppression of NF-kB
activities.
TRAF2DN sensitizes HHMSX cells to apoptosis induced
by anisomycin or actinomycin D
Given the relative modest changes seen in degree of
UV-induced cell death upon TRAF2DN expression we
have explored possible sensitization to other chemo-
therapeutic compounds. Treatment with Taxol arrested
the melanoma cells in G2/M phase, but did not aect
level of apoptosis in the TRAFDN expressing cells
(Figure 5a). Similarly, treatment with cis-platinum did
not change level of cell death in TRAFDN expressing
cells (Figure 5a). Conversely, actinomycin D or
anisomycin caused apoptosis, which further increased
(2 – 2.5-fold) in cells that express TRAF2DN. Forty per
cent of TRAF2DN expressing HHMSX human
melanoma cells underwent apoptosis in response to
anisomycin 18 h after treatment (Figure 5a). These
results indicate that whereas sensitization by
TRAF2DN is not aecting responsiveness of the
melanoma cells to certain chemotherapeutic agents,
there is greater sensitivity to treatments by ribotoxic
drugs such as anisomycin. These results also indicate
that a greater sensitization of melanoma cells by
TRAFDN expression is achieved by anisomycin
compared with UV-irradiation. Of interest is that
sensitization to actinomycin D (data not shown), but
not to anisomycin-treatment could be attenuated by
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the antagonistic antibodies to TNFa (Figure 5b). These
observations suggest that the sensitization of melano-
ma cells to UV or actinomycin D by TRAF2DN
expression, utilize dierent apoptotic regulatory path-
ways than the sensitization to anisomycin treatment.
TRAF2DN sensitizes HHMSX cells to apoptosis induced
by the radiomimetic drug neocarzinostatin (NCS)
Important to the characterization of melanoma
sensitization to treatment is to evaluate the eect of
radiation, to which late-stage melanoma are notor-
iously resistant. To this end we used the radiomimetic
drug NCS (Peixoto and Andreo, 2000). Treatment of
melanoma cells with low doses (5500 ng/ml) did not
alter degree of apoptosis (data not shown). At doses of
0.5 mg/ml or higher NCS caused a noticeable degree of
apoptosis (9, 30 and 68% apoptosis in response to 0.5,
1 and 4 mg/ml, respectively; Figure 6). Forced expres-
sion of TRAF2DN eciently increased the degree of
apoptosis (from 9 – 18; 30 – 80 and from 68 – 100%;
Figure 6). These finding illustrate the ability to sensitize
a highly resistant melanoma cells to the radiomimetic
drug NCS upon expression of TRAF2 that lacks the
ring finger domain.
Discussion
The present study identifies TRAF2 as a target for
sensitizing selective melanoma cells to UV irradiation,
radiomimetic and ribotoxic drug treatment. In as much
Figure 3 HHMSX/TRAF2DN cells possess prolonged and elevated p38/ATF2 activity, and ATF2-Jun-dependent transcription.
(a) Western blot analysis was performed on cell extracts prepared from two HHMSX cell lines permanently transfected with
TRAF2DN for detection of TRAF2DN. (b) Total cell extracts (75 mg) from HHMSX/TRAF2DN and HHMSX-neo (control) cells
were isolated 0 – 2 h after UVC treatment and analysed by Western blotting using Abs against phospho-p38 MAPK, a control p38,
phospho-ATF2 and control ATF2. (c) A solid-phase protein kinase assay was performed in vitro using GST-ATF2 immobilized on
glutathione-agarose beads as a substrate and total protein extracts (10 mg) from HHMSX-neo and HHMSX/TRAF2DN cells
isolated 0 – 2 h after UVC irradiation. (d) HHMSX-neo or HHMSX/TRAF2DN cells were transiently transfected with the indicated
reporter constructs: 56Jun2tk-Luc, 7615 TNF-Luc or 26NF-kB-Luc (0.75 mg) in the presence of 0.25 mg of pCMV-b-gal.
Twenty-four hours after transfection cells were irradiated with UVC (60 J/m2) and after an additional 16 h, proteins were prepared
and used for the analysis of luciferase and b-galactosidase activity. The normalized ratio of luciferase to b-galactosidase activity is
shown. (e) Western blot analysis of TNFa expression in HHMSX cells before and after UVC irradiation was carried out on total
cell extracts (75 mg). (f) Degree of apoptosis levels of HHMSX-neo and HHMSX/TRAF2DN cells in response to dierent doses of
UVC irradiation were determined 24 h after treatment. Data shown represents experiments that were reproduced over five times.
Apoptosis of HHMSX cells that were subjected to UV-irradiation in the presence or absence of antagonistic anti-TNFa mAb
(aTNFa) (5 mg/ml) is shown
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this finding highlights two novel observations. First, we
show that altered TRAF2 activity eciently sensitizes
melanoma cells to radiation and thus identifies new
target regulation of apoptosis in this tumor type.
Second, we demonstrate that sensitization is also seen
in response to anisomycin or actinomycin D, thus by
identifying that ribotoxic compounds may serve as
potentially eective drugs for combination treatment of
melanoma tumors. Through the analysis of HHMSX
cells we demonstrate that alteration of TRAF2
activities eciently increase degree of radiomimetic
and ribotoxic drug-induced apoptosis. HHMSX was
selected out of five melanoma cell lines that we have
studied here, of which three exhibit a constitutively
high level of TRAF2 expression that is not altered in
response to UV-irradiation. These observations coin-
cide with the finding that melanoma cells that exhibit
reduced levels of TRAF2 after UV-irradiation are
more sensitive and reveal greater degree of cell death in
response to UV treatment.
The ability to use ring finger-deleted form of TRAF2
to increase sensitivity to irradiation depends on the
related changes in the degree of TNFa expression.
Given the role of p38/ATF2 in the regulation of TNFa
expression and since TRAF2DN increases p38 activ-
ities, the elevated expression of TNFa is expected to
result in increased expression of TNFR1. Interestingly,
TRAF2 deficiency in TRAF27/7 mice was also
accompanied by substantial increase of TNFa expres-
sion (Yeh et al., 1997; Tyers and William, 1999).
Changes in TNFa expression alone may not suce to
increase sensitization to UV-irradiation, since cell
ability to resist such treatment also depends on the
nature of alternate apoptotic and anti-apoptotic path-
ways. For these reasons HHMSX, in which expression
of Fas is almost undetectable, and in which TNFR1 is
Figure 4 Inhibition of p38 or activation of NF-kB attenuates TRAF2DN sensitization of melanoma cells to apoptosis. (a)
HHMSX-neo and TRAFDN cells were treated with the pharmacological inhibitor of p38, SB203580 (5 mM) prior to UV-irradiation
and changes in the degree of apoptosis was determined 18 and 64 h after irradiation. (b) and (c), Forced expression of IKKbS178E in
TRAF2DN expressing melanoma cells was followed by analysis of NF-kB DNA binding activity by EMSA (b) and NF-kB-
mediated luciferase reporter activity (c). (d) Degree of apoptosis in TRAF2DN expressing melanoma cells that were co-transfected
with the constitutively active IKKbS178E construct and pGFP is shown
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present at moderate levels, serves as an ideal example.
The lack of changes in Fas levels was best reflected by
the observation that TNF-TNFR serves as the primary
apoptotic pathway in response to UV treatment of
these melanoma cells. In as much our finding suggest
that the analysis of Fas and TNF expression may allow
identifying melanomas which may be sensitized to
treatment with selective radiomimetic or ribotoxic
(anisomycin) drugs, upon modulation of TRAF2
activities.
What are the precise changes elicited by the TRAF2
construct that lacks ring finger are yet to be elucidated.
TRAF2 may belong to the growing list of ring finger
proteins, which possess E3 ligase activities (Tyers and
Jorgensen, 2000). In as much, deletion of the ring
would abrogate this activity, while preserving some of
other TRAF2 functions. This may explain why
TRAF2DN expression caused elevated activity of p38
signaling cascade as reported here. TRAF2DN ability
to activate p38 requires ASK1/2, suggesting that the
TRAF2-ASK-p38 pathway is activated upon
TRAF2DN expression.
Further insight to the possible mechanisms by which
TRAF2DN sensitizes HHMSX cells to radiomimetic
and ribotoxic treatment comes from the finding that
both the pharmacological inhibitor of p38 and the
constitutively active form of IKKb eciently attenu-
ated TRAF2DN-mediated sensitivity to UV-treatment.
These findings are in line with the increase in p38
activity observed upon TRAF2DN expression, with the
increased TNFR1 expression by p38 eector, ATF2
(Ivanov and Ronai, 1999), and with the downregula-
tion of NF-bB activities by p38 (Zandi et al., 1997).
Inhibition of NF-kB activity by adenoviral vector was
also reported to sensitize melanoma cells to apoptosis
(Bakker et al., 1999).
Sensitization of melanoma cells by anisomycin or
actinomycin D with altered activities of p38/ATF2,
achieved via TRAF2DN resembles the ability to
sensitize tumor cells to ribotoxic stress using combina-
Figure 5 Eect of ribotoxic compounds and chemotherapeutic drugs on apoptosis of TRAFDN expressing melanoma cells. (a)
Levels of apoptosis in HHMSX neo and TRAFDN expressing cells after exposure to anisomycin (10 mg/ml), actinomycin D (5 mM),
cis-platinum (1.2 mM) or Taxol (5 mg/ml). In all cases analysis was performed 18 h after treatment. (b) Levels of apoptosis in
HHMSX/TRAFDN cells which were pretreated with normal IgG or anti-TNFa Ab before anisomycin treatment
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tion of anisomycin, histone deacetylase and cyclin
dependent kinase inhibitors both in culture and in nude
mice (Ruller et al., 1999). Given that alteration of
apoptosis represents one of the crucial targets in tumor
development, identifying additional targets, as shown
here for TRAF2, points to new means one may




Human melanoma LU1205 cells were maintained in
MCDB153/L15 medium (4 : 1) supplemented with 5% fetal
bovine serum, L-glutamine and antibiotics. In addition,
medium for WM1552 early-phase human melanoma cells
contained insulin (5 mg/ml). FEMX, HHMSX and THX,
human melanoma-derived cells are maintained in RPMI1640
medium supplemented with 10% FCS. HHMSX/TRAF2DN
cells were maintained in the same medium supplemented with
G418 (200 mg/ml).
Chemicals
Actinomycin D, cycloheximide, anisomycin and paclitaxel
(Taxol) were purchased from Sigma. The radiomimetic drug
neocarzinostatin (NCS) was obtained from Kayaku Co.
(Tokyo, Japan). The inhibitor of p38 (SB203580) was
purchased (Calbiochem).
Stable transfection and selection
pcDNA3-neo (Invitrogen, Carlsbad, CA, USA) or pcDNA3-
FLAG-TRAF2DN constructs encoding the truncated form of
TRAF2 cDNA without the first 86 aa and (Relaix et al.,
1998) were electroporated (230 V, 1050 mF) into HHMSX
cells as previously described (Ronai et al., 1998). HHMSX-
neo control and and HHMSX/TRAF2DN cell lines were
created as a mixed population of G418-resistant clones.
Transient transfection and luciferase assay
Transient transfection of reporter constructs (0.75 mg)
[26NF-kB-Luc, 56Jun2tk-Luc, 56TRE-tk-Luc and vector
tk-Luc (van Dam et al., 1998), 7615 TNF-Luc and its
mutated variants (Rhoades et al., 1992)] together with the
indicated expression vectors and pCMV-bgal (0.25 mg) into
56105 LU1205 melanoma cells was performed using
Figure 6 Eect of radiomimetic drug NCS on apoptosis of TRAFDN expressing melanoma cells. HHMSX cells were subjected to
treatment with the indicated concentrations of NCS and degree of apoptosis was determined after 48 h as detailed in Materials and
methods
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Lipofectamine (GIBCO–BRL). Luciferase activity was
determined using the Luciferase assay system from Promega
(Madison, WI, USA). Values were normalized based on b-
galactosidase levels. Constitutive active forms of IKK were
previously described (Zandi et al., 1997).
Treatment and apoptosis studies of melanoma cells
Cells were exposed to UVC at indicated doses as previously
described (Ivanov and Ronai, 1999). Cycloheximide (10 mg/
ml; Sigma, St. Louis, MO, USA), SB203580 (1 – 10 mM)
(Calbiochem, San Diego, CA, USA) and recombinant TNFa
(10 ng/ml) (Pharmingen, San Diego, CA, USA) were used to
treat melanoma cells. Antagonistic monospecific antibodies
against human Fas (clone G254 – 274) and against TNFa
(clone Mab1; Pharmingen, San Diego, CA, USA) or TNFR1
(R&D Systems, Minneapolis, MN, USA) were added at final
concentrations of 1 – 10 mg/ml.
Apoptosis analysis was performed by flow cytometry of PI-
stained cells as described previously (Nicoletti et al., 1991).
The percentage of cells to the left of the diploid G0/1 peak,
characteristic of hypodiploid cells that have partially lost
DNA, was calculated as percentage of apoptotic cells and is
referred to in Results as per cent of apoptosis. Melanoma
cells (56105) were transiently cotransfected by expression
vectors together with marker plasmid encoding Green
Fluorescent Protein, pGFP (1 and 0.25 mg, respectively)
using Lipofectamine (GIBCO–BRL). DNA fragmentation
analysis of GFP positive cells was performed using cells fixed
in 1% paraformaldehyde, treated with 70% ethanol, washed
with PBS and stained with PI. Surface expression of Fas was
determined using anti-Fas-PE Ab (PharMingen, CA, USA)
and flow cytometric analysis.
Western blotting analysis
Cell lysates (50 – 100 mg protein) were resolved on 10%
SDS–PAGE, transferred to nitrocellulose and processed
according to the standard manual. The polyclonal Abs used
were against p38 and phospho-p38 (Thr180/Tyr182), ATF2
and phospho-ATF2 (Thr71) from New England BioLabs.
Polyclonal anti-TRAF2 and anti-BclXL antibodies were
purchased from Santa Cruz Biotechnology. The primary
Abs were used at dilution 1 : 1000 to 1 : 3000. The secondary
Abs were anti-rabbit or anti-mouse IgG conjugated to
horseradish peroxidase (dilution 1 : 5000). Signals were
detected using the ECL system (Amersham, Arlington
Heights).
Kinase assay
Protein kinase assays were carried out using a fusion protein,
GST-ATF2, as a substrate as previously described (Fuchs et
al., 1998). Briefly, the GST-ATF2 fusion proteins (0.5 mg/
assay) were bound to glutathione-sepharose beads before
addition of melanoma proteins as the source of p38/JNK
(10 mg/assay) in the presence of kinase buer (20 mM
HEPES, pH 7.6, 1 mM EGTA, 1 mM dithiothreitol, 2 mM
MgCl2, 2 mM MnCl2, 5 mM NaF, 1 mM NaVO3, 50 mM
NaCl) at room temperature for 15 min. The beads were
pelleted and washed extensively with PBST (150 mM NaCl,
16 mM sodium phosphate, pH 7.5, 1% Triton X-100, 2 mM
EDTA, 0.1% b-MeOH, 0.2 mM phenylmethylsulfonyl fluor-
ide and 5 mM benzamidine) before incubation with
[g-32P]ATP (50 c.p.m./fmol; Amersham) in the presence of
kinase buer. Following extensive washing, the phosphory-
lated ATF2 was boiled in SDS sample buer and the eluted
proteins were run on a 15% SDS-polyacrylamide gel. The gel
was dried and phosphorylation of the ATF2 substrate was
determined by autoradiography, followed by quantification
with a phosphorimager (BioRad).
Abbreviations
AP1: activator protein-1; ATF2: activating transcription
factor 2; NF-kB: nuclear factor kappa B; IKK: inhibitor
nuclear factor kappa B kinase; PI: propidium iodide; TNFa:
tumor necrosis factor alpha; TNFR: tumor necrosis factor
receptor; TRAF2: tumor necrosis factor receptor asso-
ciated factor 2; GFP: green fluorescent protein; IkB:
inhibitor NF-kB; MAPK: mitogen-activated protein ki-
nase; MFI: medium fluorescence intensity; MKK: MAPK
kinase; CHX: cycloheximide; NCS: neocarzinostatin.
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